quantic69/iStock via Getty Images
Alvotech (NASDAQ:ALVO) and Dr. Reddy’s Laboratories (NYSE:RDY) have entered into a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar candidate to Keytruda (pembrolizumab) for global markets.
Keytruda (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales
US Defense Secretary Pete Hegseth announced yet another deadly strike on a boat accused of ferrying drugs in the eastern...
Seeking Alpha's Disclaimer: The earnings call insights are compilations of earnings call transcripts and other content available on the Seeking...
Palantir reported a third-quarter earnings beat this week, and during his victory lap, CEO Alex Karp provided a window into...
Hamilton Insurance Group (HG) said on Tuesday its board has approved a $150 million increase to the company’s existing share...
Another crypto company is headed to Wall Street. Animoca Brands, a Hong Kong-based blockchain developer and investor, plans to list...
At Fortune’s Most Powerful Women summit last month, he said he expects full attention from everyone in the room. “If you...
The first and only national digital and print magazine that connects individuals, families, and businesses to Fee-Only financial advisers, accountants, attorneys and college guidance counselors.
